Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tetra
- Development stage
- Unknown
- Lead developer
- Ophthalogix
- Administration
- Ophthalmic
01
Overview
Tetra is an ocular amniotic membrane tissue (AMT) graft developed by Ophthalogix, an Evologics company. It is designed for use by eye care professionals in the treatment of various ophthalmic conditions. As a biological graft, Tetra provides a natural scaffold that supports the migration and adhesion of epithelial cells while delivering essential growth factors and cytokines that promote healing and reduce inflammation and scarring. It is used in the management of conditions such as corneal ulcers, persistent epithelial defects, and following pterygium excision. Tetra is classified as a medical device or tissue product rather than a traditional pharmaceutical drug.
- Brand names
- Tetra
Beyond the preview
Go deeper on Tetra.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tetra.